Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

INTRODUCTION: Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non‐steroidal anti‐inflammatory drug trials in AD and m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Alzheimers Dement (N Y)
Main Authors: Potter, Huntington, Woodcock, Jonathan H., Boyd, Timothy D., Coughlan, Christina M., O'Shaughnessy, John R., Borges, Manuel T., Thaker, Ashesh A., Raj, Balaibail A., Adamszuk, Katarzyna, Scott, David, Adame, Vanesa, Anton, Paige, Chial, Heidi J., Gray, Helen, Daniels, Joseph, Stocker, Michelle E., Sillau, Stefan H.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2021
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988877/
https://ncbi.nlm.nih.gov/pubmed/33778150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12158
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares